Cornerstone Capital Management Holdings LLC. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 819,719 shares of the biopharmaceutical company’s stock after selling 101,427 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.06% of Gilead Sciences worth $58,017,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Penserra Capital Management LLC lifted its holdings in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares in the last quarter. American Beacon Advisors Inc. bought a new position in Gilead Sciences in the 1st quarter worth about $143,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares during the last quarter. Capstone Investment Advisors Netherlands B.V. bought a new position in Gilead Sciences in the 2nd quarter worth about $172,000. Finally, Sterling Investment Advisors Ltd. bought a new position in Gilead Sciences in the 2nd quarter worth about $184,000. 76.23% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $74.22 on Friday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $96,951.29, a PE ratio of 7.75, a PEG ratio of -1.24 and a beta of 1.13. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the company earned $2.75 EPS. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.80%. Gilead Sciences’s payout ratio is 23.69%.

In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 494,999 shares of company stock worth $37,404,139. 1.30% of the stock is owned by corporate insiders.

A number of equities analysts have weighed in on GILD shares. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Deutsche Bank restated a “buy” rating and issued a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, August 31st. Berenberg Bank set a $86.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, August 29th. Finally, Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price on the stock. in a research note on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $85.11.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/10/cornerstone-capital-management-holdings-llc-sells-101427-shares-of-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.